Biochemical pathway of antigen processing by HLA class II molecules in B cell lymphomas Leukemia (2004) Non-Hodgkin's B cell lymphomas are characterised by the expression of both human leukocyte antigen (HLA) class I and class II molecules. As HLA class II molecules are constitutively expressed only in professional antigen-presenting cells (APCs), B lymphomas are considered as professional APCs. Contrary to the majority of tumour cells that usually express only HLA class I molecules, B cell lymphomas can also be considered as an original model for cellular immunotherapy involving the CD4T lymphocyte component in direct contact with tumour cells. We and others previously reported that CD4T lymphocytes may play a direct role by cell-cell contact and could not only directly target tumour cells expressing HLA class II molecules (review by Wang 1 ) but also by differentiation or cell cycle progression. Moreover, modifications of the second messengers in the signalling pathway via class II HLA-DR molecules were previously described in B lymphomas. 2 This could be of interest in the field of cellular immunotherapy where APCs and particularly dendritic cells are used to generate specific antitumour CD4 and CD8T lymphocytes.
HLA class II molecules biosynthesis begins in the endoplasmic reticulum. They are subsequently targeted at compartments intermediately between late endosomes and lysosomes called MIIC (for MHC class II compartment) where antigen loading can take place, before targeting to the cell surface (review by Alfonso and Karlsson 3 ). During this intracellular pathway, the Invariant chain (Ii) blocks the peptide-binding groove of HLA-DR molecules and is sequentially degraded until the generation of a peptide called CLIP (Class II associated Invariant chain peptide). The loading of antigenic peptides instead of CLIP is then catalysed by HLA DM in the MIIC, which is in turn modulated by HLA DO (selectively expressed in B lymphocytes and a specific negative modulator of HLA DM outside the MIIC).
In this study we explored the key components of the biochemical pathway leading to the expression of antigenic peptide-loaded HLA-DR molecules at the cell surface in various types of B cell lymphomas and compared them with normal B lymphocytes from spleen and peripheral blood. Lymph node biopsies were obtained from 16 patients with four diffuse large B cells (DLCL), four mantle cells (MCL), four follicular (FL), and four lymphocytic (LL) lymphomas. Diagnosis was established according to the WHO classification. B lymphocytes, except for peripheral blood (positive purification), were purified by negative immunomagnetic selection (final population 498% CD19 þ cells). A total of 16 lymphomas expressed HLA-DR molecules at their surface (Table 1) . Different populations of HLA-DR complexes were exposed at the cell surface of B lymphocytes. These include peptide-loaded HLA-DR complexes and HLA-DR/CLIP complexes. Strikingly, four MCLs and three DLCLs presented no or few HLA-DR/CLIP complexes at their surface when compared to other lymphomas and normal B lymphocytes (Table 1) . As HLA-DR/CLIP complexes are usually found at the cell surface of normal B lymphocytes, 4 this raises the possibility that differences or abnormalities exist in the intracellular processing of peptides and loading on HLA-DR molecules, leading to complete proteolysis of the invariant chain and complete removal of CLIP.
HLA-DR molecules loaded with a stably bound peptide remained associated as a 55 kDa ab complex in the presence of SDS at room temperature, and dissociated into free a and b chains after boiling (non-boiled NB and boiled B, Figure 1a) . HLA-DR molecules from all lymphomas contained SDS resistant complexes, demonstrating the presence of peptides-loaded complexes (Figure 1a) . HLA-DM were also present in all types of lymphomas, but were lower expressed in the sample from LL (Figure 1b) . Remarkably, we observed a constant lower expression or absence of HLA DO in the four MCL compared to other samples and normal B lymphocytes (Figure 1b) . A representative experiment for each type of lymphomas is shown (Figure 1 ).
Based upon the observation of few or no HLA-DR/CLIP at the cell surface in some lymphomas and the fact that CLIP dissociates from HLA-DR at acidic pH, we hypothesised that HLA-DR molecules could travel via more acidic compartments on their pathway to the cell surface. Intracellular localisation of HLA-DR was therefore explored by confocal microscopy and paralleled with a specific marker of lysosomes LAMP-1 ( Figure 2) . Two different patterns emerged: one consisting of a group with no colocalisation of HLA-DR and LAMP-1 (FL, LL, DLCL 1, normal B lymphocytes) and a second group (DLCL 2-4 and MCL 1-4) where HLA-DR was largely colocalised in acidic compartments labelled with LAMP-1, confirming our hypothesis. Pictures from nonmalignant B lymphocytes from spleen and peripheral blood showed a very weak co-localisation (Figure 2) .
Unlike classical solid tumours, the constitutive expression of HLA class II molecules on their cell surface allow malignant B lymphocytes from non-Hodgkin's B cell lymphomas to interact with CD4T lymphocytes infiltrating the tumour, and thus 
Figure 2
Purified B lymphocytes adhered onto polyL-lysine-coated slides were fixed by formaldehyde, permeabilised by Triton X-100 and incubated with a polyclonal rabbit serum against HLA-DRab complexes and a mAb against LAMP-1, respectively, revealed with FITC-conjugated swine anti-rabbit antibodies and Cyanin 3 conjugated goat anti-mouse antibodies. Pictures were acquired on an LSM410 Axiovert200 confocal microscope (ZEISS) with LSM410 software from Zeiss. A minimum of 20 pictures were obtained from one sample (80-100 pictures for each lymphoma type). A representative cell for each cell type is shown. represent a possible way for the tumour to manipulate the immune system. To the best of our knowledge, this is the first study of the major components of the biochemical pathway for antigen presentation by class II molecules: HLA-DR, DM and DO, in non-Hodgkin's B lymphomas. Previous studies on HLA class II in human B cell lymphomas mainly focused on surface expression of the molecules or genetic alterations of the HLA region leading to loss of expression, 5 and showed that they occur in exceptional cases. Interestingly, alterations in antigen presentations by HLA class II molecules consisting in unusual abundance of HLA-DR/CLIP complexes at the cell surface have been observed in freshly purified cells from samples in Hodgkin's disease. 6 In conclusion, regarding the colocalisation of HLA-DR and LAMP-1 or not, two groups of B lymphomas emerged from this study: one is composed of FL, LL and DLCL 1, identical to normal B lymphocytes, and the other is composed of MCL 1-4 and DLCL 2-4. We suggest that a correlation can be made between the absence or the low HLA-DR/CLIP expression at the cell surface and the presence of HLA-DR in lysosomes. Since HLA-DR molecules are targeted at the acidic lysosomal compartment in the second group, the final repertoire of peptides presented to the cell surface could be altered as compared to normal B lymphocytes. Whereas this alteration influences CD4T lymphocytes, recognition remains to be investigated but is supported by reports from H2O knockout mice where low level of H2O could be associated with changes in the peptide repertoire processed. 7 Finally, we suggest our data should be considered in the field of cellular immunotherapy. Indeed, the tumoral antigenic peptides processed and presented by HLA class II molecules in normal APCs may be totally different from the ones presented by MCL and DLCL. Exosomes directly generated from malignant B lymphocytes and expressing HLA-DR molecules already loaded with the adequate peptides would therefore be of interest to arm APCs as previously reported in solid tumours. 
